0.28
-0.01780001(-6.08%)
Currency In USD
| Previous Close | 0.29 |
| Open | 0.29 |
| Day High | 0.3 |
| Day Low | 0.28 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 3.58M |
| Average Volume | 10.09M |
| Market Cap | 16.63M |
| PE | -0.29 |
| EPS | -0.96 |
| Moving Average 50 Days | 0.45 |
| Moving Average 200 Days | 0.48 |
| Change | -0.02 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of February 21, 2026 at a share price of $0.275. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $4.89 as of February 21, 2026 at a share price of $0.275.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
GlobeNewswire Inc.
Jan 22, 2026 12:45 PM GMT
Expands CNSide Clinical License in State of PennsylvaniaHOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceut
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
GlobeNewswire Inc.
Jan 21, 2026 9:15 PM GMT
HOUSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today an
Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering
GlobeNewswire Inc.
Jan 14, 2026 1:00 PM GMT
HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today an